A 64-year-old man with reduced ejection fraction heart failure (LVEF 30%) after an anterior MI is clinically stable. He is on an ACE inhibitor and beta blocker at target doses but no other HF medications. According to contemporary Canadian heart failure guidelines, what is the next best pharmacologic step to reduce mortality and hospitalisation?